Abstract
Children with acute severe asthma exacerbation are at risk of developing respiratory failure. Moreover, conventional aggressive management might be futile in acute severe asthma requiring intubation and invasive ventilation. The aim of this review is to detail evidence on the use of ketamine in childhood asthma exacerbations. A search of the MEDLINE, EMBASE, and Cochrane databases was performed, using different combinations of the following terms: ketamine, asthma, use, exacerbation, and childhood. In addition, we searched the references of the identified articles for additional articles. We then reviewed titles and included studies that were relevant to the topic of interest. Finally, the search was limited to studies published in English and Spanish from 1918 to June 2015. Due to the scarcity in the literature, we included all published articles. The literature reports conflicting results of ketamine use for acute severe asthma in children. Taking into consideration the relatively good safety profile of the drug, ketamine might be a reasonable option in the management of acute severe asthma in children who fail to respond to standard therapy. Furthermore, pediatricians and pediatric emergency clinicians administering ketamine should be knowledgeable about the unique actions of this drug and its potential side effects.
Introduction
The Global Strategy for Asthma Management and Prevention Guidelines describes asthma as a chronic inflammatory disorder of the airways associated with increased airway hyperresponsiveness, recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night/early morning.Citation1 Moreover, asthma is classified as one of the most common chronic diseases in children.Citation2 Acute severe asthma, previously referred to as status asthmaticus, is a phenomenon in which asthmatics do not respond to bronchodilators and corticosteroids,Citation3 and it comprises ~500,000 yearly admissions to the pediatric intensive care unit (PICU).Citation4–Citation6 In the USA, asthma affects >7 million children, of which 4 million experience at least one attack of asthma exacerbation.Citation7 Fortunately, the prevalence of asthma attacks is not on the rise. This might be attributed to the dissemination of national asthma guidelines that emphasize on preventive measures.Citation7–Citation9 The prevalence of asthma in children is 9.6% compared to 7.7% in adults. Moreover, children who live below poverty level have higher prevalence of asthma compared to children who belong to families with a higher socioeconomic status.Citation7 The reported prevalence of asthma deaths for children and adults younger than 35 years was 3.4 per million in 2007. In addition, children with asthma missed 10.5 million school days in 2008 due to their disease.Citation7
Children with acute severe asthma exacerbations are at risk of developing respiratory failure, and conventional aggressive management might be futile requiring intubation and invasive ventilation.Citation10,Citation11 Ketamine has been described as a sedative for intubation and invasive ventilation in children with severe asthma attacks.Citation12 It provides stability to airway reflexes and cardiac performance while simultaneously inducing amnesia, analgesia, and decline in airway resistance.Citation13 Moreover, ketamine might be useful in managing severe asthma attacks in children when conventional management fails.Citation13,Citation14 In this review, we discuss the effectiveness and safety of ketamine in children with refractory asthma attacks.
The aim of this review is to detail evidence on the use of ketamine in childhood asthma exacerbations.
Methods
We carried out a search of the MEDLINE, EMBASE, and Cochrane databases, using different combinations of the following terms: ketamine, asthma, use, exacerbation, and childhood. In addition, we searched the references of the identified articles for additional articles. We then reviewed the abstracts and titles and included studies that were relevant to the topic of interest. Finally, the search was limited to studies published in English and Spanish from 1918 to June 2015. Outcome measures were analyzed using the following clinical findings: evidence, dose and duration of ketamine use, safety, secondary effects, and mortality. Due to the scarcity in the literature, we included all published articles (randomized control trials, reviews, case reports, retrospective studies, and Cochrane). The literature reports conflicting results of ketamine use for acute severe asthma in children.
Discussion
Ketamine
Ketamine is a drug mainly used for the induction and maintenance of anesthesia. It has also been used for the induction of sedation, as a pain killer, as an antidepressant, for the management of bronchospasm, and as a treatment for complex regional pain syndrome. One of the advantages of ketamine is that breathing, heart function, and, according to some authors, airway reflexes stay functional during the drug infusion.Citation13 It is an excellent choice of sedative for children requiring rapid sequence intubation for life-threatening asthma.Citation14–Citation18 In 1962, the World Health OrganizationCitation19,Citation20 listed ketamine as an essential medicine. Ketamine, previously known as CI581, is a water-soluble agent, noncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist, a derivative of phencyclidine, and it has two enantiomers, S(+)-ketamine and R(−)-ketamine.Citation21,Citation22 Commercially available ketamine is marketed as a racemic mixture comprising equal amounts of (S)- and (R)-ketamine. The d-S(−) isomer of ketamine has three- to fourfold the potency and fivefold better affinity to NMDA when compared to the l-R(−) isomer.Citation21 Intramuscular and intravenous ketamine has a high bioavailability with a half-life of 2–3 hours and a rapid onset of action reaching peak plasma concentration in 60 seconds. Moreover, it has a short duration of action (10–15 minutes after a single bolus injection).Citation22,Citation23 On the other hand, oral ketamine has a low (up to 20%) bioavailability, tardy absorption, and slow peak ratio.Citation24–Citation26
In addition to being an NMDA receptor antagonist, ketamine also acts on opioid receptors and monoamine transporters. Moreover, ketamine is a dissociative agent,Citation27,Citation28 that is, absorbable by intravenous, intramuscular, oral, and topical routes due to both its hydrophilic and lipophilic characteristics.Citation29 It undergoes first-pass metabolism and is metabolized in the liver by CYP3A4 (major), CYP2B6 (minor), and CYP2C9 (minor) isoenzymes mainly into norketamine (through N-demethylation) and dehydronorketamine.Citation26 Dehydronorketamine and norketamine are the two most common metabolites detected in urine.Citation30 Benzodiazepines such as diazepam and other CYP3A4 inhibitors can potentially increase plasma concentrations of ketamine.Citation25 In addition, other commonly used medications in pediatric medicine such as epinephrine, doxapram, fentanyl, isocarboxazid, phenelzine, and magnesium sulfate can interact with ketamine.Citation31,Citation32
Mechanism of action of ketamine as an airway relaxant and bronchodilator
The proposed mechanisms of airway relaxation contain ketamine inhibition of postsynaptic nicotinic or muscarinic receptors, voltage-sensitive Ca2+ channel blockage, induced inhibition of catecholamine reuptake, and increased catecholamine concentrations.Citation10,Citation33 Moreover, other suggested mechanisms of airway relaxation include suppression of macrophage function of phagocytosis, its oxidative ability, and inflammatory cytokine production.Citation34 Ketamine bolsters bronchorrhea and bronchodilation assisting in the clearance of mucus plugs.Citation35 It also functions as a bronchodilator when administered in low dose.Citation36 Moreover, it has also been proven that ketamine at sedative doses is effective in the management of severe asthma attacks averting the need for endotracheal intubation.Citation14–Citation16 Investigations conducted on murine models showed that ketamine has protective effects on high airway reactivity in asthma and on allergen-triggered airway inflammation.Citation37 In a different murine study, Zhu et alCitation38 evaluated the effect of ketamine inhalation on bronchial hyperresponsiveness and airway inflammation in a brown Norway rat model of ovalbumin-induced allergic asthma. The study concluded that ketamine in a nebulized form using an ultrasonic nebulizer significantly reduced airway inflammation, allergen-mediated airway hyperreactivity, and airway inflammatory cell infiltration into the bronchoalveolar lavage fluid. Moreover, the authors noted marked suppression of interleukin-4 in the bronchoalveolar lavage fluid and expression of inducible nitric oxide synthase and the concentration of nitric oxide in the inflamed airways from ovalbumin-treated rats. Moreover, ketamine relaxes and decreases bronchomotor tone perhaps due to interference with a Ca2+ crucial step necessary to maintain the contraction caused by histamine.Citation39,Citation40 Ketamine has been successfully used in patients with severe bronchospasm who do not respond to traditional management, such as β2-agonists, corticosteroids, and anticholinergics.Citation10,Citation15,Citation41 Moreover, the same studies have shown that administration of ketamine is beneficial in ventilated and in nonventilated pediatric patients with acute asthma exacerbation.Citation10,Citation15,Citation41
Effect of ketamine on respiration
The impact of ketamine on respiration varies, and the literature lacks homogeneity with regard to this issue. Bourke et alCitation42 concluded that ketamine, in low dose, depresses ventilation but has no influence on the respiratory response to increasing levels of carbon dioxide. However, Hamza et alCitation43 found that ketamine is a respiratory depressant, particularly after an intravenous bolus dose, and it reduces the responsiveness of respiratory center to CO2. Moreover, Shulman et alCitation44 mentioned that the use of ketamine does not alter functional residual capacity and minute ventilation in children.
Ketamine in acute severe asthma
Ketamine was initially synthesized in 1962 by Calvin Stevens, and the Federal Drug Administration agency eventually approved the use of ketamine as an anesthetic agent in 1970.Citation19,Citation45 In 1971, Betts and ParkinCitation46 described complete resolution of wheezing in a preschooler with severe asthma after the administration of ketamine. The dose of ketamine initially used was 75 mg/kg intramuscularly, followed by 10 mg of administered intravenously approximately every 15 minutes adding up to a total of 115 mg. In 1972, Corssen et alCitation47 monitored the effect of ketamine use in 44 asthmatic children and adults. The induction dose of ketamine (1%) used was 1–2 mg/kg intravenously and 0.5–1 mg/kg at 15–30 minutes intervals for maintenance. The study concluded that ketamine protects against exacerbation of asthma, improves acute bronchospasm when administered with other anesthetic agents, and ameliorates bronchospasm in children and adults with respiratory distress. In 1986, Strube and HallamCitation48 reported about a 13-year-old girl who was admitted to the PICU with status asthmaticus and failed to respond to conventional bronchodilator therapy to relieve her bronchospasm. The dose of ketamine used was 40 µg/kg/min for a period of 8 hours. The patient significantly improved after the ketamine infusion and obviated the need for intubation and mechanical ventilation. In 1992, SarmaCitation49 presented two patients with acute severe asthma who did not respond to standard therapy. Ketamine was used as a bolus dose of 0.75 mg/kg, followed by the same dose over 10 minutes, resulting in amelioration of bronchospasm. In 1993, Jahangir et alCitation50 conducted a cohort study to assess the benefits of providing complete postoperative analgesia in asthmatics with ketamine delivered in subanesthetic doses (6.10–6.41 µg/kg/min). The study concluded that respiratory functions were favorable for asthmatics. Complications of ketamine were reported as minimal. In 1994, Hemmingsen et alCitation51 evaluated ketamine in the treatment of bronchospasm during mechanical ventilation via a prospective, placebo-controlled, double-blinded trial. Fourteen mechanically ventilated patients with bronchospasm were randomly selected to receive either ketamine 1 mg/kg or saline placebo. The study concluded that the ketamine-treated patients showed an improvement in air entry, in PO2 and in PCO2, indicating that ketamine might be effective in the treatment of bronchospasm during mechanical ventilation. In 1996, Youssef-Ahmed et alCitation52 researched the continuous infusion of ketamine in mechanically ventilated children with refractory bronchospasm in 17 infants and children who were admitted to the PICU. The ketamine dose was 2 mg/kg as an IV bolus, followed by continuous infusions of 20–60 µg/kg/min. The authors concluded that continuous infusion of ketamine (40±31 hours) to mechanically ventilated patients with refractory bronchospasm markedly improved the dynamic compliance of the chest and gas exchange. In 2001, Petrillo et alCitation15 conducted a prospective observational study to assess the effects of adding ketamine to standard emergency department therapy for patients with status asthmaticus. The study included ten children who did not respond to conventional therapy. The ketamine dose used was 1 mg/kg intravenously for the loading dose, followed by a continuous infusion of 0.75 mg/kg/h (12.5 µg/kg/min) for 1 hour. The authors concluded that there was a significant reduction in clinical asthma scores by 37%. In addition, the median respiratory rate and oxygen requirement improved, but the peak expiratory flow (PEF) did not show significant improvement. Forty percent of the children involved in the study experienced minor side effects, such as diffuse flushing, moderate increase in blood pressure, and mild hallucinations. In 2003, Heshmati et alCitation41 conducted a prospective observational study to evaluate the use of ketamine in severe status asthmaticus in the intensive care unit. Ketamine was administered to eleven patients (aged 15–40 years old) with status asthmaticus in respiratory failure. The received ketamine dose was 1 mg/kg intravenously as a loading dose, followed by a continuous infusion of 1 mg/kg/h for 2 hours. Peak airway pressures, PaCO2 and PaO2, were monitored prior to ketamine administration, 15 minutes after administration, and 2 hours after infusion of ketamine. The authors concluded that the mean peak airway pressure and PaCO2 declined significantly (P<0.005) and PaO2 raised significantly (P<0.005) after 15 minutes and 2 hours of ketamine infusion. In 2006, Denmark et alCitation14 published two cases of severe asthma exacerbations in prepubertal children. The authors concluded that the administration of a bolus of intravenous ketamine followed by a continuous infusion of a relatively large dose of ketamine resulted in prompt improvement, averting the need for mechanical ventilation. In 2008, Shlamovitz and HawthorneCitation16 presented a case of severe asthma exacerbation who did not respond to conventional therapy. The authors concluded that the patient improved dramatically after the administration of intravenous ketamine (0.75 mg/kg intravenous bolus followed by continuous drip of 0.15 mg/kg/h). In 2012, Jat el alCitation53 reported a case of a 2-month-old male who presented with respiratory distress. The patient did not respond to oxygen supplementation, adrenaline nebulization, salbutamol nebulization, oral prednisolone, ipratropium nebulization, intravenous hydrocortisone, terbutaline infusion, magnesium sulfate, and aminophylline. Intravenous ketamine was used as 1 mg/kg bolus followed by continuous infusion at the rate of 10 µg/kg/min. The ketamine infusion rate was eventually increased to 15 µg/kg/min. With the administration of ketamine, oxygen saturation improved and wheezing and respiratory distress decreased. Terbutaline, aminophylline and ketamine were weaned off in 48 hours. In 2014, Agrawal and ShrivastavaCitation54 published a case of a 2-year-old female who presented with respiratory failure due to severe bronchospasm. The child who was found to be H1N1 positive did not respond to ipratropium and budesonide nebulization, intravenous hydrocortisone, magnesium sulfate, subcutaneous adrenaline, and intravenous infusion of terbutaline and aminophylline. Ketamine was eventually administered as initial bolus (0.5 mg/kg) followed by continuous infusion (0.5 mg/kg/h) and increased gradually up to 2 mg/kg/h. The child showed improvement in peak inspiratory pressure, gas exchange, and SpO2 and decrease in wheezing within a 4-hour period. The magnesium, aminophylline, and terbutaline infusions were weaned off gradually in 24 hours.
On the other hand, other studies showed that the infusion of ketamine does not provide benefits over the conventional therapy in children with moderate-to-severe asthma exacerbation. For instance, Allen and MaciasCitation36 conducted a double-blinded, randomized, placebo-controlled trial to evaluate children aged 2–18 years old who presented to a pediatric emergency department with an acute asthma exacerbation. Sixty-eight children met the criteria: 33 children were randomized to receive ketamine infusion and 35 children received normal saline. Exclusion criteria included focal infiltrate on radiograph, fever >39°C (102°F), or any glucocorticoid use in the last 72 hours. All children received three treatments with albuterol, ipratropium bromide, and a dose of oral or parenteral glucocorticoids. The group of children randomized to receive ketamine were administered an intravenous bolus of 0.2 mg/kg of ketamine, followed by a 2-hour ketamine infusion at 0.5 mg/kg/h. The study showed that the mean decrease in the pulmonary index scores at the end of the infusion was 3.2±2.0 in the ketamine group versus 3.6±1.3 in the placebo group (difference of mean 0.4; 95% confidence interval [CI] −0.4 to 1.3). There were no reported short-term adverse effects. Moreover, Howton et alCitation55 carried out a prospective, randomized, double-blinded, placebo-controlled trial to evaluate the efficacy of ketamine as a bronchodilator in acute severe asthma. The study included 53 patients aged between 18 years and 65 years with acute asthma exacerbation and PEF <40% after three doses of albuterol nebulization. Methylprednisolone, oxygen, and continuous nebulized albuterol were provided to all the patients. Thereafter, all patients received either ketamine 0.2 mg/kg bolus, followed by a continuous intravenous infusion at 0.5 mg/kg/h for 3 hours, or a placebo bolus and infusion for the same duration. The bolus dose of ketamine was eventually decreased to 0.1 mg/kg due to dysphoric reactions in some patients. There was statistically and clinically marked improvement in forced expiratory volume at the end of the first second, PEF, Borg score, and respiratory rate within each group. However, there was no significant difference in outcome between both groups (power, 80%). The authors concluded that there was no increased bronchodilator effect compared with conventional therapy in treating acute severe asthma in the emergency department. Furthermore, Jat and ChawlaCitation56 conducted a Cochrane study to assess the efficacy of ketamine compared to placebo and reported that there was no intervention or standard care for the management of acute severe asthma in children who had failed standard therapy. RCTs comparing ketamine to placebo or conventional management in children with acute asthma exacerbation who failed conventional therapy were included in the study. Only one study was found eligible for inclusion. The authors reported no significant difference in oxygen saturation, respiratory rate, hospital admission rate, and the need for endotracheal intubation between the ketamine group (0.2 mg/kg intravenous bolus over 1–2 minutes, followed by a 0.5 mg/kg/h continuous infusion for 2 hours) and the placebo group.
Side effects of ketamine
Ketamine must be used with discretion, since unwanted effects include hypoventilation, hypertension, laryngospasm, and emergence agitation.Citation35 When given intravenously, ketamine must be given slowly to prevent transient respiratory depression and laryngospasm.Citation57 Ketamine must be used with caution in patients with seizure disorders, since it may decrease the seizure threshold.Citation58 Moreover, ketamine increases cerebral blood flow, which may intensify intracranial and intraocular pressures.Citation59 Undesirable recovery reactions, including atrial fibrillation and agitation, have been well documented in the adult literature.Citation33,Citation60 However, the literature states that the side effects of ketamine are uncommon in children and teenagers, and they are typically mild.Citation34,Citation61,Citation62 Ketamine administered as a bolus dose ranging from 0.1 mg/kg to 2 mg/kg followed by continuous infusion (0.15–2.5 mg/kg/h) displays no major adverse effects. The minor side effects reported include hallucinations, dysphoria, mild disruptions in heart rate and blood pressure in few patients, and increased secretions.Citation10,Citation31
Ketamine neurotoxicity
There have been serious concerns on the possible detrimental neurotoxic side effects of exposures to ketamine in children, such as brain neuronal destruction and eventually learning disability.Citation63–Citation65 In 1999, Ikonomidou et alCitation66 have suggested that ketamine and its derivatives might lead to brain cells’ apoptosis, especially during the active brain development in immature animals. Other studies also showed that the administration of several doses of ketamine to neonatal rats might result in brain apoptosis.Citation67,Citation68 Braun et alCitation69 studied the mechanism of cytotoxicity in different human neuronal cells and lymphocytes in vitro. The investigation concluded that ketamine at millimolar concentrations can trigger apoptosis through the mitochondrial pathway and not mediated through the NMDA receptor. Finally, clinical findings support that cognitive disorders may ensue ketamine chronic useCitation70 but rarely reported with acute use.Citation71
Conclusion
Ketamine is a good choice of sedative for children requiring rapid sequence intubation for life-threatening asthma. However, the literature reports conflicting results of its use in acute severe asthma in children. Taking into consideration the relatively good safety profile of the drug, ketamine might be a reasonable option in the management of acute severe asthma in children who fail to respond to standard therapy. Pediatricians and pediatric emergency clinicians administering ketamine should be knowledgeable about the unique actions of this drug and its potential side effects. Moreover, larger randomized controlled trials are required to better study the efficacy of ketamine in the management of acute severe asthma in children.
Disclosure
The authors report no conflicts of interest in this work.
References
- GINA [webpage on the Internet]Global Strategy for Asthma Management and Prevention Available from: http://www.ginasthma.org/pdf/GINA-Pocket-2010a.pdfAccessed February 26, 2015
- RustGZhangSReynoldsJInhaled corticosteroid adherence and emergency department utilization among Medicaid-enrolled children with asthmaJ Asthma20135076977523734973
- KazaVBandiVGuntupalliKKAcute severe asthma: recent advancesCurr Opin Pulm Med20071311717133117
- KellyCSAndersenCLPestianJImproved outcomes for hospitalized asthmatic children using a clinical pathwayAnn Allergy Asthma Immunol20008450951610831004
- BirkenCSParkinPCMacarthurCAsthma severity scores for preschoolers displayed weaknesses in reliability, validity, and responsivenessJ Clin Epidemiol2004571177118115567635
- ManninoDMHomaDMAkinbamiLJMoormanJEGwynnCReddSCSurveillance for asthma – United States, 1980–1999MMWR Surveill Summ200251113
- AkinbamiLJMoormanJELiuXAsthma prevalence, health care use, and mortality: United States, 2005–2009Natl Health Stat Report20113211421355352
- AkinbamiLJSchoendorfKCParkerJUS childhood asthma prevalence estimates: the impact of the 1997 National Health Interview Survey redesignAm J Epidemiol20031589910412851220
- AkinbamiLThe state of childhood asthma, United States, 1980–2005Adv Data200638112417180851
- WernerHAStatus asthmaticus in children: a reviewChest20011191913192911399724
- SlyRMDecreases in Hispanic and non-Hispanic asthma mortalityAnn Allergy Asthma Immunol200696767916440536
- MaddoxRPSeupaulRAIs ketamine effective for the management of acute asthma exacerbations in children?Ann Emerg Med20146330931024268906
- GreenSMRobackMGKennedyRMKraussBClinical practice guideline for emergency department ketamine dissociative sedation: 2011 updateAnn Emerg Med20115744946121256625
- DenmarkTKCraneHABrownLKetamine to avoid mechanical ventilation in severe pediatric asthmaJ Emerg Med20063016316616567251
- PetrilloTMFortenberryJDLingerJFSimonHKEmergency department use of ketamine in pediatric status asthmaticusJ Asthma20013865766411758894
- ShlamovitzGZHawthorneTIntravenous ketamine in a dissociating dose as a temporizing measure to avoid mechanical ventilation in adult patient with severe asthma exacerbationJ Emerg Med20114149249418922662
- L’HommedieuCSArensJJThe use of ketamine for the emergency intubation of patients with status asthmaticusAnn Emerg Med1987165685713565871
- RockMJReyes de la RochaSL’HommedieuCSTruemperEUse of ketamine in asthmatic children to treat respiratory failure refractory to conventional therapyCrit Care Med1986145145163698618
- Ketamine [webpage on the Internet]Center for Substance Abuse Research (CESAR)University of Maryland Available from: http://www.cesar.umd.edu/cesar/drugs/ketamine.aspAccessed December 25, 2014
- WHOWHO Model List of Essential Medicines18th edGenevaWorld Health Organization2013
- LiYCollerJKHutchinsonMRThe CYP2B6*6 allele significantly alters the N-demethylation of ketamine enantiomers in vitroDrug Metab Dispos2013411264127223550066
- StevensonCKetamine: a reviewUpdate Anaesth2005202529
- ReichDLSilvayGKetamine: an update on the first twenty-five years of clinical experienceCan J Anaesth1989361861972650898
- BrunetteKEAndersonBJThomasJWiesnerLHerdDWSchuleinSExploring the pharmacokinetics of oral ketamine in children undergoing burns proceduresPaediatr Anaesth20112165366221355949
- QuibellRPrommerEEMihalyoMTwycrossRWilcockAKetamineJ Pain Symptom Manage20114164064921419322
- SinnerBGrafBMKetamineSchüttlerJSchwildenHModern Anesthetics Handbook of Experimental Pharmacology182BerlinSpringer2008313333
- KohrsRDurieuxMEKetamine: teaching an old drug new tricksAnesth Analg199887118611939806706
- BergmanSAKetamine: review of its pharmacology and its use in pediatric anesthesiaAnesth Prog199946102010551055
- AroniFIacovidouNDontasIPourzitakiCXanthosTPharmacological aspects and potential new clinical applications of ketamine: reevaluation of an old drugJ Clin Pharmacol20094995796419546251
- LiJHVicknasingamBCheungYWTo use or not to use: an update on licit and illicit ketamine useSubst Abuse Rehabil201116112024474851
- Ketamine [webpage on the Internet]Medscape Available from: http://reference.medscape.com/drug/ketalar-ketamine-343099#3Accessed December 7, 2015
- Ketamine [webpage on the Internet]BasowDSWaltham, MA UpToDate. Available from: http://www.uptodate.com/contents/ketamine-pediatric-drug-information?source=search_result&search=ketamine&selectedTitle=2~148#F185702Accessed December 8, 2015
- GoyalSAgrawalAKetamine in status asthmaticus: a reviewIndian J Crit Care Med20131715416124082612
- ChangYChenTLSheuJRChenRMSuppressive effects of ketamine on macrophage functionsToxicol Appl Pharmacol2005204273515781291
- WhitePFWayWLTrevorAJKetamine – its pharmacology and therapeutic usesAnesthesiology1982561191366892475
- AllenJYMaciasCGThe efficacy of ketamine in pediatric emergency department patients who present with acute severe asthmaAnn Emerg Med200546435015988425
- ZhuMMQianYNZhuWProtective effects of ketamine on allergen-induced airway inflammatory injure and high airway reactivity in asthma: experiment with ratsZhonghua Yi Xue Za Zhi2007871308131317727773
- ZhuMMZhouQHZhuMHEffects of nebulized ketamine on allergen-induced airway hyperresponsiveness and inflammation in actively sensitized Brown-Norway ratsJ Inflamm (Lond)200741017480224
- SatoTHirotaKMatsukiAZsigmondEKRabitoSFThe role of the N-Methyl-D-Aspartic acid receptor in the relaxant effect of ketamine on tracheal smooth muscleAnesth Analg199887138313889842833
- HirotaKSatoTRabitoSFZsigmondEKMatsukiARelaxant effect of ketamine and its isomers on histamine-induced contraction of tracheal smooth muscleBr J Anaesth1996762662708777108
- HeshmatiFZeinaliMBNorooziniaHAbbacivashRMahooriAUse of ketamine in severe status asthmaticus in intensive care unitIran J Allergy Asthma Immunol2003217518017301376
- BourkeDLMAlitLASmithTCRespiratory interactions of ketamine and morphineAnesthesiology1987661531563101549
- HamzaJEcoffeyCGrossJBVentilatory response to CO2 following intravenous ketamine in childrenAnesthesiology1989704224252493753
- ShulmanDBeardsmoreCSAronsonHBGodfreySThe effect of ketamine on the functional residual capacity in young childrenAnesthesiology1985625515563887993
- MorrisHWallachJFrom PCP to MXE: a comprehensive review of the non-medical use of dissociative drugsDrug Test Anal2014661463224678061
- BettsEKParkinCEUse of ketamine in an asthmatic child: a case reportAnesth Analg19715034204215103778
- CorssenGGutierrezJRevesJGHuberFCJrKetamine in the anesthetic management of asthmatic patientsAnesth Analg Curr Res197251588596
- StrubePJHallamPLKetamine by continuous infusion in status asthmaticusAnaesthesia198641101710193789345
- SarmaVJUse of ketamine in acute severe asthmaActa Anaesthesiol Scand1992361061071539472
- JahangirSMIslamFChowdhurySNAzizLGhaniMAKetamine infusion for postoperative analgesia: a prospective cohort study in asthmaticsBangladesh Med Res Counc Bull19931921278257399
- HemmingsenCNielsenPKOdoricoJKetamine in the treatment of bronchospasm during mechanical ventilationAm J Emerg Med1994124174208031424
- Youssef-AhmedMZSilverPNimkoffLSagyMContinuous infusion of ketamine in mechanically ventilated children with refractory bronchospasmIntensive Care Med1996229729768905436
- JatKRAzadCGuglaniVUse of ketamine for refractory wheezing in an infantIndian Pediatr20124958758822885445
- AgrawalAShrivastavaJIntravenous ketamine for refractory bronchospasm precipitated by H1N1 infectionFront Pediatr201422424765619
- HowtonJCRoseJDuffySZoltanskiTLevittMARandomized, double-blind, placebo-controlled trial of intravenous ketamine in acute asthmaAnn Emerg Med1996271701758629747
- JatKRChawlaDKetamine for management of acute exacerbations of asthma in childrenCochrane Database Syst Rev201211CD00929323152273
- KraussBGreenSMProcedural sedation and analgesia in childrenLancet200636776678016517277
- CorssenGLittleSCTavakoliMKetamine and epilepsyAnesthes Analg197453319335
- JollyTMcLeanHSUse of ketamine during procedural sedationJ Infus Nurs20123537738223132086
- UmunnaBPTekwaniKBarounisDKettanehNKulstadEKetamine for continuous sedation of mechanically ventilated patientsJ Emerg Trauma Shock20158111525709246
- WattsKChavasseRJLeukotriene receptor antagonists in addition to usual care for acute asthma in adults and childrenCochrane Database Syst Rev20125CD00610022592708
- WathenJERobackMGMackenzieTBothnerJPDoes midazolam alter the clinical effects of intravenous ketamine sedation in children? A double-blind, randomized, controlled emergency department trialAnn Emerg Med200036657958811097698
- SlikkerWJrZouXHotchkissCEKetamine-induced neuronal cell death in the perinatal rhesus monkeyToxicol Sci200798114515817426105
- Jevtovic-TodorovicVHartmanREIzumiYEarly exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficitsJ Neurosci200323387688212574416
- MazoitJXRoulleauPBaujardCIsoflurane-induced neuroapoptosis in the neonatal rhesus macaque brain: isoflurane or ischemia-reperfusion?Anesthesiology201011351245 author reply 1245–124620966672
- IkonomidouCBoschFMiksaMBlockade of NMDA receptors and apoptotic neurodegeneration in the developing brainScience1999283539870749872743
- ZouXPattersonTASadovovaNPotential neurotoxicity of ketamine in the developing rat brainToxicol Sci200910814915819126600
- ShiQGuoLPattersonTAGene expression profiling in the developing rat brain exposed to ketamineNeuroscience201016685286320080153
- BraunSGazaNWerdehausenRKetamine induces apoptosis via the mitochondrial pathway in human lymphocytes and neuronal cellsBr J Anaesth2010105334735420659914
- MorganCJRiccelliMMaitlandCHCurranHVLong-term effects of ketamine: evidence for a persisting impairment of source memory in recreational usersDrug Alcohol Depend20047530130815283951
- UboguEESagarSMLernerAJMadduxBNSuarezJIWerzMAKetamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicityEpilepsy Behav20034707512609230